$69.85 +0.25 (%) Biomarin Pharmaceutical Inc - NASDAQ

Sep. 19, 2014 | 04:00 PM

Partner Headlines

  1. BioMarin Weathers The Storm

    Benzinga | Aug. 6, 2014 | 16:02PM EST
  2. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  3. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  4. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga | Jun. 9, 2014 | 09:41AM EST
  5. Benzinga's Top Upgrades

    Benzinga | Jun. 9, 2014 | 07:52AM EST
  6. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  7. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga | Feb. 27, 2014 | 12:26PM EST
  8. Top Trending Tickers On StockTwits For February 18

    Benzinga | Feb. 18, 2014 | 10:22AM EST
  9. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  10. You Can No Longer Ignore Biotech

    GuruFocus | Feb. 7, 2014 | 17:32PM EST
  11. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
  12. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)

    Benzinga | Jan. 11, 2014 | 11:46AM EST
  13. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns

    Benzinga | Nov. 27, 2013 | 11:10AM EST
  14. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook

    Benzinga | Nov. 27, 2013 | 07:50AM EST
  15. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD | Nov. 20, 2013 | 12:11PM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 20, 2013 | 08:26AM EST
  17. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment of Patients with Morquio A Syndrome

    Benzinga | Nov. 19, 2013 | 17:04PM EST
  18. BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic Drugs Advisory Committee

    Benzinga | Nov. 19, 2013 | 07:11AM EST
  19. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga | Nov. 12, 2013 | 16:41PM EST
  20. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts | Nov. 7, 2013 | 12:54PM EST
  21. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer

    Benzinga | Oct. 31, 2013 | 05:58AM EST
  22. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

    Benzinga | Oct. 25, 2013 | 15:36PM EST
  23. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients

    Benzinga | Oct. 24, 2013 | 10:05AM EST
  24. Roche

    IBD | Oct. 23, 2013 | 18:47PM EST
  25. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC International Conference

    Benzinga | Oct. 20, 2013 | 17:01PM EST
  26. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga | Oct. 11, 2013 | 14:33PM EST
  27. Orphan Drugs: No (Payer) News Is Good News

    YCharts | Oct. 9, 2013 | 14:08PM EST
  28. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ECC 2013

    Benzinga | Sep. 29, 2013 | 10:46AM EST
  29. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga | Sep. 25, 2013 | 12:52PM EST
  30. Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate

    Benzinga | Sep. 20, 2013 | 06:45AM EST
  31. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga | Sep. 19, 2013 | 17:47PM EST
  32. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness | Sep. 19, 2013 | 11:34AM EST
  33. Benzinga's Volume Movers

    Benzinga | Sep. 19, 2013 | 10:52AM EST
  34. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 19, 2013 | 08:09AM EST
  35. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate Risk/Reward, Expected Slower Data Flow

    Benzinga | Sep. 18, 2013 | 10:27AM EST
  36. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 18, 2013 | 08:08AM EST
  37. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

    Benzinga | Sep. 14, 2013 | 11:47AM EST
  38. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares

    GuruFocus | Feb. 5, 2013 | 12:06PM EST
  39. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 14,000 Shares

    GuruFocus | Jan. 24, 2013 | 14:06PM EST
  40. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5,000 Shares

    GuruFocus | Jan. 23, 2013 | 08:35AM EST
  41. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga | Jan. 22, 2013 | 06:47AM EST
  42. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 3,000 Shares

    GuruFocus | Jan. 8, 2013 | 14:07PM EST
  43. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5,000 Shares

    GuruFocus | Jan. 3, 2013 | 10:36AM EST
  44. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin Pharmaceutical

    Benzinga | Jan. 2, 2013 | 07:14AM EST
  45. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 17,000 Shares

    GuruFocus | Dec. 27, 2012 | 14:36PM EST
  46. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 9,000 Shares

    GuruFocus | Dec. 21, 2012 | 12:38PM EST
  47. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 5,000 Shares

    GuruFocus | Dec. 17, 2012 | 06:51AM EST
  48. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5,000 Shares

    GuruFocus | Dec. 14, 2012 | 12:35PM EST
  49. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 6,000 Shares

    GuruFocus | Dec. 11, 2012 | 13:55PM EST
  50. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral with $46 PT

    Benzinga | Dec. 7, 2012 | 05:46AM EST
Trading Center